Hematopoietic cells are often obtained from bone marrow, peripheral blood, and umbilical cord blood, albeit in very limited numbers. The ability to expand hematopoietic progenitor populations can be difficult to achieve. A successful expansion must provide sufficient numbers of fully functional hematopoietic progenitor cells that are able to self-renew and differentiate into all functional blood cells.
Provides Optimal Performance
Xeno-free, serum-free basal medium for human hematopoietic progenitor cell culture
Supports maintenance of CD34+ hematopoietic stem and progenitor cell populations
Optimized expansion of hematopoietic stem and progenitor cell populations
Designed and manufactured to facilitate transfer from research to clinic. Supported by robust raw material controls and supply chain management
FDA, Federal, and State registered - cGMP-compliant manufacture
EN ISO 13485:2016 certified
Extensive QC testing including functionality, sterility (USP <71>), and endotoxin (USP <85>)
Drug Master Files (DMFs) filed with the FDA – available upon request
Custom sizes and packaging available upon request.
Contact us for international pricing and custom formulations.
Figure 1 CD34+ hematopoietic progenitor cells derived from human cord blood were cultured in PRIME-XV Hematopoietic Cell Basal XSFM or a commercially-available xeno-free expansion medium, both supplemented with a cocktail of cytokines (TPO, SCF, FLT-3L, IL-3 and IL-6). After 3, 7 and 9 days, the TNC (A) and fold expansion (B) of CD34+ cells were quantified.
This product is shipped at 2-8°C with cold packs. Upon receipt, store immediately at 2-8°C and protect from light.
Handle using aseptic techniques to avoid contamination. Unopened liquid medium is stable for 12 months from date of manufacture, as indicated on the label.